This fifth episode takes a look at some of the next vaccines in the development pipeline that could be equally important when it comes to ending the pandemic with a selection of different vaccines. We’ll look at some of the challenges to continue ongoing clinical trials now that vaccines are already publicly available. Experts discuss GSK and Sanofi’s recombinant protein vaccine that had some disappointing interim results in December, and they also discuss why Australia's now abandoned vaccine was triggering false positives for HIV. We also take a quick glimpse at the inactivated vaccines coming out of China, and the future potential of DNA vaccines that use special devices. Finally we take a look further down the road to whether developing and manufacturing Covid-19 vaccines might be economically viable for smaller players in the race in the long term. Guest profiles and timestamps available at https://thecovaxfiles.com